Farzana Perwad

Dietary and Serum Phosphorus Regulate Fibroblast Growth Factor 23 Expression and 1,25-Dihydroxyvitamin D Metabolism in Mice

Farzana Perwad, Nasreen Azam, Martin Y. H. Zhang et al. · Endocrinology · 2005 · 428 citations · Full text

Medicine, Nutrition, Nutritional Sciences +11

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

Erik A. Imel, Francis H. Glorieux, Michael P. Whyte et al. · The Lancet · 2019 · 367 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +4

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

Karl Insogna, Karine Briot, Erik A. Imel et al. · Journal of Bone and Mineral Research · 2018 · 340 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1α-hydroxylase expression in vitro

Farzana Perwad, Martin Y. H. Zhang, Harriet S. Tenenhouse et al. · American Journal of Physiology-Renal Physiology · 2007 · 302 citations

Medicine, Endocrinology, Nephrology +17

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Anthony A. Portale, Thomas O. Carpenter, Maria Luisa Brandi et al. · Calcified Tissue International · 2019 · 160 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17